Atara Biotherapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 225
- Market Cap
- $33.6M
- Website
- http://www.atarabio.com
- Introduction
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-c...
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis
- Conditions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Atara Biotherapeutics
- Target Recruit Count
- 26
- Registration Number
- NCT06429800
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Atara Biotherapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT06256484
- Locations
- 🇺🇸
Norton Cancer Institute - Saint Matthews, Louisville, Kentucky, United States
🇦🇺Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
🇦🇺Fiona Stanley Hospital, Murdoch, Western Australia, Australia
A Study to Evaluate Tabelecleucel in Participants with Epstein-barr Virus-associated Diseases
- Conditions
- Epstein-Barr Virus (EBV)-associated DiseasesEBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD)EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD)EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative DisordersAllogeneic Hematopoietic Cell TransplantStem Cell Transplant ComplicationsEBV+ Sarcomas
- Interventions
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Atara Biotherapeutics
- Target Recruit Count
- 190
- Registration Number
- NCT04554914
- Locations
- 🇺🇸
University of California Los Angeles (UCLA) (Adults and Pediatrics), LOS Angeles, California, United States
🇺🇸Children's Hospital of Orange County (Pediatrics [up to 25 years old]), Orange, California, United States
🇺🇸Lucile Packard Children's Hospital Stanford (Pediatrics only), Palo Alto, California, United States
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Atara Biotherapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT03769467
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Stanford Hospital and Clinics, Palo Alto, California, United States
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
- First Posted Date
- 2018-01-09
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Atara Biotherapeutics
- Target Recruit Count
- 66
- Registration Number
- NCT03394365
- Locations
- 🇺🇸
University of Maryland School of Medicine (Adults only), Baltimore, Maryland, United States
🇺🇸Arthur M. Blank Hospital (Pediatrics), Atlanta, Georgia, United States
🇺🇸City of Hope (Adults and Pediatrics), Duarte, California, United States
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Atara Biotherapeutics
- Target Recruit Count
- 134
- Registration Number
- NCT03283826
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
🇺🇸University of California, San Diego, La Jolla, California, United States
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
- Conditions
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Atara Biotherapeutics
- Registration Number
- NCT03010332
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
- Conditions
- Epstein-Barr Virus (EBV) InfectionsLymphoproliferative DisordersEBV+ Associated LymphomaEBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Epstein-Barr ViremiaLymphoma, AIDS-relatedEpstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID)Leiomyosarcoma (LMS)Nasopharyngeal Carcinoma (NPC)Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID)
- First Posted Date
- 2016-07-04
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Atara Biotherapeutics
- Registration Number
- NCT02822495
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- Atara Biotherapeutics
- Target Recruit Count
- 87
- Registration Number
- NCT01498484
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Atara Biotherapeutics
- Target Recruit Count
- 58
- Registration Number
- NCT00002663
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States